ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES

• US 20130261287A1
• Filed: 03/11/2013
• Published: 10/03/2013
• Est. Priority Date: 12/05/2008
• Status: Abandoned Application

• Current Assignee: Lpath Inc. (Boston Scientific Corporation)
• Original Assignee: Jonathan Michael Wojciak, Roger A. Sabbadini, Tom Huxford
• Inventors: SABBADINI, Roger A., HUXFORD, Tom, WOJCIAK, Jonathan Michael
• Application Number:
  US13/793,255
• Publication Number:
  US 20130261287A1
• Time in Patent Office: Days
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: G01N 2405/08 Sphingolipids
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743
• CPC Class Codes: G16B 5/00 ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Abstract

Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Claims

1. A method of designing an optimized antibody to a lipid, comprising:

a. providing an amino acid sequence of at least one variable region of a heavy or light chain of a first anti-lipid antibody, optionally a humanized antibody, wherein the anti-lipid antibody is specific for a first lipid, optionally a sphingolipid or a lysolipid, and wherein optionally at least one complementarity-determining region within the variable region is identified;

b. replacing one or more amino acids within the at least one variable region with a different amino acid to yield a variant amino acid sequence, wherein the amino acid replacement(s) is(are) within a complementarity-determining region;

c. preparing a second anti-lipid antibody containing the variant amino acid sequence, wherein the amino acid sequences of the first and second anti-lipid antibodies differ only in the variant amino acid sequence;

d. determining one or more activity criteria of the second antibody, optionally by molecular modeling, ELISA, or surface plasmon resonance, wherein at least one of the activity criteria is optionally binding affinity for the first lipid, binding affinity for a second lipid, or specificity for the first lipid or specificity for a second lipid, wherein the first and second lipids are different lipid species; and

e. selecting an optimized antibody based on one or more of the activity criteria, wherein the optimized antibody is the second antibody,

wherein the method is optionally performed in silico.

2. A method according to claim 1 further comprising use of three-dimensional structural information about the binding of the first antibody and the first lipid to select a location and/or identity of the amino acid replacement(s), optionally wherein the three-dimensional structural information is molecular modeling data or x-ray crystallography data.

3. An optimized antibody made according to claim 1, wherein the optimized antibody optionally specifically binds to a bioactive lipid, wherein the bioactive lipid optionally is a sphingolipid or a lysolipid.

4. A method according to claim 1 wherein the first anti-lipid antibody is LT1009, optionally wherein the one or more amino acids replaced is/are selected from the group consisting of:

aspartic acid at positions 30, 31, and 32, glutamic acid at position 50, aspartic acid at position 92, leucine at position 94 and phenylalanine at position 96, all of the light chain; and

threonine at position 33, histidine at position 35, alanine at position 50, serine at position 52, histidine at position 54, isoleucine at position 56, lysine at position 58, phenylalanine at position 97, tyrosine at position 98, threonine at position 100A or tryptophan at position 100C, all of the heavy chain.

5. An optimized antibody variant of LT 1009 prepared according to claim 4, optionally wherein one or more amino acids within one or more of the variable regions of LT1009 is replaced with a different amino acid to yield a variant amino acid sequence, and wherein the one or more replaced amino acids is selected from the group consisting of:

aspartic acid at positions 30, 31 and 32, glutamic acid at position 50, aspartic acid at position 92, leucine at position 94 and phenylalanine at position 96, all of the light chain; and

threonine at position 33, histidine at position 35, alanine at position 50, serine at position 52, histidine at position 54, isoleucine at position 56, lysine at position 58, phenylalanine at position 97, tyrosine at position 98, glycine at position 99, serine at position 100, threonine at position 100A or tryptophan at position 100C, all of the heavy chain.

12. An optimized antibody variant of LT1009 of claim 5 comprising one or more replacements selected from the group consisting of:

replacement of aspartic acid at position 30 in the light chain with alanine, replacement of aspartic acid at position 32 in the light chain with alanine, replacement of glutamic acid at position 50 in the light chain with alanine or glutamine, replacement of phenylalanine at position 96 in the light chain with alanine;

replacement of histidine at position 35 in the heavy chain with alanine, glutamine or glutamic acid.

6. A method selected from the group consisting of:

a. a method of designing a consensus anti-lipid antibody specifically reactive with a target bioactive lipid, comprising;

(i) identifying at least a first CDR amino acid sequence from a first parent antibody species specifically reactive with a target bioactive lipid and at least a second CDR amino acid sequence from a second parent antibody species specifically reactive with the target bioactive lipid, wherein the first and second CDR amino acid sequences are both CDRH1, both CDRH2, both CDRH3, both CDRL1, both CDRL2 or both CDRL3 CDR amino acid sequences;

(ii) aligning the first CDR amino acid sequence and second CDR amino acid sequence to determine a consensus CDR amino acid sequence; and

(iii) engineering a nucleic acid sequence that encodes the consensus CDR amino acid sequence into a gene comprising a variable region of an antibody heavy or light chain, thereby designing a consensus anti-lipid antibody specifically reactive with a target bioactive lipid, and, optionally,

(iv) producing an antibody or antibody fragment that binds the target bioactive lipid; and

b. a method of designing an antibody variant or antibody fragment variant specifically reactive with a target bioactive lipid, comprising;

(i) providing a first structural representation comprising an initial representation of a target bioactive lipid in binding association with an antibody or antibody fragment specifically reactive with a source bioactive lipid, wherein the target bioactive lipid and the source bioactive lipid are the same or a different bioactive lipid species, wherein the initial representation comprises three-dimensional structural information for the antibody or antibody fragment optionally derived from molecular modeling data or x-ray crystallography data; and

(ii) substituting at least one amino acid residue represented in the first structural representation with a different amino acid residue in order to identify a second structural representation comprising a subsequent representation of the target bioactive lipid in modified binding association with the modified antibody or antibody fragment, thereby designing an antibody variant or antibody fragment variant that is specifically reactive with the target bioactive lipid, wherein the antibody variant or antibody fragment optionally has a modified binding association, optionally an improved binding association, for the bioactive lipid.

7. A method according to claim 6 performed in silico.

8. An antibody or antibody fragment, optionally a humanized antibody or fragment thereof, produced according to claim 6(a).

9. A method according to claim 6(b) wherein the target bioactive lipid is (i) the same as the source bioactive lipid or (ii) different than the source bioactive lipid, wherein in either case the target bioactive lipid optionally is S1P.

10. A method according to claim 6(b) further comprising engineering one or more nucleotide sequences that encode the antibody variant or antibody fragment variant that binds the target bioactive lipid, and optionally further comprising producing the antibody variant or antibody fragment variant.

11. An antibody or antibody fragment specifically reactive with a target bioactive lipid, or a composition comprising such an antibody or antibody fragment, wherein in either case the antibody or antibody fragment is produced in accordance with claim 10.